Hepatic Sugar Metabolism Measured by PET/CT in Patients and Healthy Subjects
Hepatic Glucose Metabolism Measured by FDG PET/CT in Patients With Liver Disease and Healthy Subjects
1 other identifier
observational
13
1 country
1
Brief Summary
The investigators wish to determine the lumped constant (LC), which is a correction factor necessary for converting measurements of hepatic FDG metabolism (measured by PET) to those of regular glucose in patients with cirrhosis and healthy subjects. Working hypothesis
- LC for FDG in liver tissue is not significantly different from unity in healthy subjects
- LC for FDG in liver disease is significantly different from LC in healthy liver
- Insulin changes the LC for FDG in liver tissue, but not by the same factor in liver disease and healthy subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2011
CompletedFirst Submitted
Initial submission to the registry
June 8, 2011
CompletedFirst Posted
Study publicly available on registry
June 9, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2012
CompletedJune 26, 2012
June 1, 2012
1.1 years
June 8, 2011
June 25, 2012
Conditions
Keywords
Study Arms (2)
Patients with chronic liver disease
Inclusion criteria * Age between 40 and 70 years * BMI between 20 and 26 Exclusion Criteria * Diabetes mellitus * Glucose intolerance * Medical treatment of portal hypertension * People who have undergone surgery for obesity * Pregnancy
Healthy subjects
Inclusion criteria * Age between 40 and 70 years * BMI between 20 and 26 Exclusion Criteria * Diabetes mellitus * Glucose intolerance * Medical treatment of portal hypertension * People who have undergone surgery for obesity * Pregnancy
Interventions
Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
Eligibility Criteria
Recruited via 2 newspapers: Århus Onsdag and Århus Stiftstidende, and so will be based in the area these newspapers are distributed in.
You may qualify if:
- Age between 40 and 70 years
- BMI between 20 and 26
You may not qualify if:
- Diabetes mellitus
- Glucose intolerance
- Medical treatment of portal hypertension
- People who have underwent surgery for obesity
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Aarhus University Hospital, PET-centre
Aarhus C, 8000, Denmark
Biospecimen
Plasma for measuring levels of ICG, insulin, c.peptide, FFA, glucagon,and 3H-glucose.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael Sørensen, MD PhD
Aarhus University Hospital, PET-centre
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2011
First Posted
June 9, 2011
Study Start
May 1, 2011
Primary Completion
June 1, 2012
Study Completion
June 1, 2012
Last Updated
June 26, 2012
Record last verified: 2012-06